



FOR IMMEDIATE RELEASE

## **ARKIS BIOSCIENCES EXHIBITS NEW SUBCUTANEOUS GUIDEWIRE ADDING TO ITS MINIMALLY INVASIVE PRODUCT LINE**

*Arkis showcases new Subcutaneous Guidewire at the Los Angeles AANS Conference, April 24-26<sup>th</sup> at booth 2047.*

LOS ANGELES, California – April 24, 2017 – Arkis BioSciences, a leading innovator in minimally invasive surgical instrumentation and next generation catheter technology for cranial neurosurgery, is exhibiting its new Subcutaneous Guidewire™ at booth 2047 of the American Association of Neurological Surgeons. The Subcutaneous Guidewire expands the company’s portfolio of guidewire products for contour tunneling and compliments the market’s enthusiasm for minimally invasive procedures. Arkis’ Subcutaneous Guidewire is designed to minimize complications and overall improve patient care by reducing surgical trauma compared to conventional procedures.

Arkis’ guidewire technology is growing in demand to assist in the reduction of rising costs from surgical complications and for improving patient outcomes. Utilizing the same proprietary technology as Arkis’ Single Pass Tunneling Guidewire™, the new Subcutaneous Guidewire is designed for tunneling a variety of complex anatomy. Procedures include cranial-caudal retroauricular implant placements, external drainage catheter routing, and torso applications including intrathecal catheter placements for drug delivery, lumboperitoneal shunt implantation, as well as plastic surgery.

“We are pleased by the demand and surgeon satisfaction of Arkis’ less invasive Tunneling Guidewire, particularly the benefit to the patient” said Chad Seaver, President and CEO, Arkis BioSciences. “We appreciate surgeons’ desire and feedback to further grow and apply the technology to other applications. We are expanding our guidewire line to support the growing demand with our new Subcutaneous Guidewire at this year’s AANS.”

## **About Arkis BioSciences**

Arkis BioSciences™ is a medical device company providing sophisticated surgical tools and implantables for advancing the neurosurgical treatments of intracranial hypertension arising from hydrocephalus, traumatic brain injury, and hemorrhagic stroke. Arkis recently introduced its Single Pass Tunneling Guidewire™ and in the near future plans to bring to market its new catheter product line. Arkis' next generation SureFlo™ EVD Catheter incorporates Endexo® polymer technology and is currently pending 510k clearance. Located in Knoxville, Tennessee, Arkis began operations in 2013 to serve the neurosurgical market to improve intracranial hypertensive patient care while overall reducing healthcare costs.

**###**

Press Contact:

Melissa Kallos

408-758-0080

[info@arkisbiosciences.com](mailto:info@arkisbiosciences.com)